. Author manuscript; available in PMC: 2021 Jul 23.

Published in final edited form as: J Med Chem. 2020 Jul 6;63(14):7569–7600. doi: 10.1021/acs.jmedchem.9b01733

Table 8.

Single Glutamate Concentration Screen for Changes in Glutamate Potency R-(+)-EU-1180–453^a

	I_{30 μM}/I_control (mean ± SEM, %) [low glutamate concentration/low glycine concentration, μM]
#	GluN2A	GluN2B	GluN2C N = 13	GluN2D N = 22
vehicle	40 ± 4 [3, 30]	84 ± 1 [3, 30]	54 ± 1 [0.5, 30]	66 ± 2 [0.5, 30]
30 μM S-(−)-EU-1180-453	45 ± 4 [3, 30] n = 11	85 ± 9 [3, 30] n = 6	57 ± 2 [0.5, 30] n = 13	72 ± 2^* [0.5, 30] n = 7
Vehicle	46 ± 5 [3, 30–100]	79 ± 1 [3, 30–100]	19 ± 3 [0.3, 10]	29 ± 2 [0.3, 10]
30 μMR-(+)-EU-1180-453	53 ± 2 [3, 30–100] n = 28	77 ± 1 [3, 30–100] n = 22	48 ± 4^* [0.3, 10] n = 13	55 ± 6^* [0.3, 10] n = 16

Data mean ± standard error for the relative current response at 0.5–3 μM glutamate compared to maximally active (30–100 μM) glutamate. 30 μM glycine was present in all solutions.

p < 0.05, paired t-test between drug and vehicle.